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in order to enhance and promote smoking cessation efforts in this population. 
Finally, the impact of inclusion of these products on the monthly prescription cap 
was also evaluated. Methods: Mississippi Medicaid FFS prescription claims data 
for the years 2012-2013 were analyzed. Only beneficiaries enrolled continuously 
in Medicaid were considered in the analysis. Dual eligibles were excluded from 
the study. Drugs dispensed were identified using National Drug Codes. Utilization 
as well as medication use patterns of nicotine replacement therapies, bupropion 
hydrochloride, and varenicline was studied. All results were reported by age, gen-
der, race, pregnancy status, and Medicaid plan ID. Distribution of beneficiaries 
in terms of number of fills for each drug was determined in order to assess new 
therapy starts and duration of therapy. Results: 366 (86.3%) of the beneficiaries 
on smoking cessation agents were prescribed bupropion while 33 (7.8%) used 
varenicline and only 18 (5.3%) used nicotine products. No other distinct patterns 
in therapy could be identified. 59 varenicline therapies were initiated but only 
13 of them continued until the third fill. In terms of the distribution of vareni-
cline therapies per beneficiary, 32 beneficiaries had only one therapy initiation 
while three beneficiaries had two therapy initiations including two starter packs 
and possibly following with continuation packs. On average, in any given month, 
65% of the eligible beneficiaries would benefit if these drugs were not included 
under the monthly prescription cap. ConClusions: A better understanding of 
utilization and treatment patterns can assist practitioners in making appropriate 
treatment decisions to help promote smoking cessation efforts in this population. 
Benefit designs such as removing copayments and/or allowing for smoking cessa-
tion therapies not to count against a prescription benefit limit will influence the 
increased utilization of these drugs.
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objeCtives: To identify and compare predictors of a successful cessation out-
come among adult smokers newly prescribed each type of smoking cessation 
medication. Methods: A retrospective cohort study was conducted using General 
Electric (GE) health care clinical data. Andersen’s Health Service Utilization model 
was used as conceptual framework. The outcome variable was being abstinent or 
not. The independent variables were categorized into predisposing, enabling, and 
need characteristics, including age, gender, race, region, payment type, specialty 
group, comorbidity, obesity, number of cigarettes smoked per day, smoking coun-
seling, and alcohol consumption. Three multivariate logistic regression models 
were conducted to identify predictors of successful outcome among adult smokers 
prescribed each type of smoking cessation medication. Results: In total, we iden-
tified 132,885 adult smokers who were newly prescribed varenicline, 4,045 adult 
smokers newly prescribed bupropion and 38,001 adult smokers newly prescribed 
nicotine replacement therapy (NRT) between 2006 and 2011. Among smokers who 
were newly prescribed varenicline, male smokers were less likely to be abstinent 
compared with female smokers (OR: 0.878, 95% CI: 0.851-0.907). Among smok-
ers being newly prescribed bupropion, smokers with depression (OR: 1.551, 95% 
CI: 1.111-2.164) were more likely to quit compared to those without depression. 
Among smokers being newly prescribed NRT, male smokers were more likely to be 
abstinent compared with female smokers (OR: 1.072, 95% CI: 1.011-1.136). Smokers 
with COPD (OR: 1.249, 95% CI: 1.121-1.392) were more likely to quit compared to 
those without COPD. ConClusions: Each different type of cessation medication 
may be particularly beneficial to certain sub-populations in real world. NRT may 
be more effective among patients with COPD compared to those without COPD. 
Bupropion may be more beneficial to smokers with depression compared to those 
without depression. NRT may be more beneficial to male smokers compared to 
female smokes. Varenicline may be more beneficial to female smokers compared 
to male smokers.
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objeCtives: To evaluate the prescribing rate of each type of smoking cessation 
medication among adult smokers in 2011. Methods: A retrospective cross-sec-
tional study was conducted using General Electric (GE) health care clinical data. 
Descriptive statistics were used to provide estimates of the prescribing rates of 
each smoking cessation medication (varenicline, bupropion, and nicotine replace-
ment therapy (NRT)) in 2011. All statistical analyses were performed using SAS 
version 9.3 (SAS Institute, Cary, NC) statistical package at a priori significance 
level of 0.05. Results: Total sample consisted of 886,604 current adult smokers 
in 2011. Among these smokers, 50,157 (5.66%) were prescribed a smoking cessation 
medication, of which, varenicline was the most commonly prescribed (n= 32,688, 
3.69%), followed by NRT (n= 17,716, 2.00%) and bupropion (n= 1,630, 0.18%). For 
those who were prescribed varenicline, 34.41% were aged between 18 and 40, 
58.03% aged between 41 and 64, and 7.56% aged more than 65. They were mostly 
comprised of white (47.84%), followed by races (47.62%) including Hispanic and 
Asian, and black (4.54%). For the smokers who were prescribed bupropion, 34.60% 
of them were aged between 18 and 40, 56.13% aged between 41 and 64, and 9.26% 
aged more than 65. Among these smokers, 44.85% of them were white, 9.33% were 
black, and 45.83% were races including Hispanic and Asian. For the smokers who 
were prescribed NRT, 32.51% of them were aged between 18 and 40, 58.69% aged 
between 41 and 64, and 8.80% aged more than 65. They were mostly comprised of 
white (47.16%), followed by races (39.37%) including Hispanic and Asian, and black 
(13.47%). ConClusions: Findings of this real world study indicate that in 2011, 
varenicline was the most commonly prescribed smoking cessation medication 
followed by NRT then bupropion.
reducing LOS, episode cost, and readmission risk in hospitalized Medicare patients 
with COPD. As such, ONS may offer an opportunity to reduce costs to Medicare 
while improving quality of outcomes.
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objeCtives: Asthma is the leading cause of activity limitation and has serious 
economic consequences on the United States health care system. The nation spends 
an estimated $56 billion in health care costs annually. Various factors are associ-
ated with high health care costs. Underuse of inhaled corticosteroids, a first-line 
therapy for asthma, may be one of the drivers to high health care costs which may 
differ according to race and ethnicity. The objective of this study is to determine 
use of inhaled corticosteroids among asthma patients, the factors associated with 
use and the economic implications of underuse of medications. Methods: A ret-
rospective study was done using 2010 and 2011 Medical Expenditure Panel Survey 
(MEPS) data to identify patients with asthma who were using inhaled corticoster-
oids expressed as days of supply of medication that cover their dosage regimen. 
Socio-demographic characteristics and total health care expenditures for these 
patients were also determined. An ordinary least square regression model was built 
to identify socio-demographic factors associated with inhaled corticosteroid use and 
health care expenditures. Results: There were 151 asthma patients identified that 
reported inhaled corticosteroids use according to availability of data on days of sup-
ply. The average days of inhaled corticosteroid use among asthma patients was 129 
days over the course of a year. Ethnicity was shown to be a significant predictor of 
inhaled corticosteroid use. Hispanics were found to have significantly lower supply 
of medication (70 days) compared to non-Hispanics. Multivariate analysis showed 
that ethnicity had no effect on total health care expenditures. ConClusions: 
Ethnic disparities were found in the use of inhaled corticosteroids among asthma 
patients. However, no difference in health care expenditures shows that access is 
not an issue for ethnic groups. Future research should investigate reasons for dis-
parities in inhaled corticosteroid use among asthma patients. The main limitation 
of this study was that it was observational in nature.
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objeCtives: Increased asthma severity is associated with worsening clinical out-
comes, but little is known about economic outcomes for very severe patients. The 
objective of this study was to assess the economic and health care utilization burden 
in the year before and after treatment escalation to GINA steps 4/5. Methods: 
Using 2003-2011 Marketscan data, three asthma treatment cohorts (age 12-75) were 
identified: omalizumab, high intensity corticosteroids (HICS; ≥ 1000 µg/day inhaled 
fluticasone equivalent or oral prednisone), and high-dose inhaled corticosteroids 
(HDICS; ≥ 500 to < 1000 µg/day fluticasone equivalent). Inclusion required “stable 
therapy”, defined as three months of therapy within the first three months after 
the index (date of first prescription), and continuous eligibility. Negative binomial, 
Tobit, OLS and Logistic regressions were used depending on the outcome variable, 
controlling for sociodemographics and chronic comorbidity. Results: Of 19,227 
patients, 856 initiated omalizumab, 6,926 initiated HICS, and 11,445 initiated HDICS. 
Patients had a heavy asthma polypharmacy burden which increased with increasing 
severity. Outpatient visits, prescription drug use, home health care and specialty 
visits increased from baseline to follow-up for all treatment cohorts; however, inpa-
tient visits and ER visits declined. Annual health care expenditures increased for all 
cohorts, markedly for omalizumab (median $9,600 to $29,800). Annual out-of-pocket 
expenses (copayments, coinsurance and deductibles) increased and were substan-
tial for all three cohorts (follow-up year: Omalizumab $2,391; HICS $1,827; HDICS 
$1,457). ConClusions: Patients utilized less outpatient care and required more 
emergency and inpatient care in the year prior to treatment escalation. Patients at 
the upper end of the asthma treatment continuum experienced a heavy polyphar-
macy burden and high out-of-pocket costs after treatment escalation to omalizumab 
or medium-high dose corticosteroids, suggesting potential room for improvement 
in treatment paradigms.
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objeCtives: This study assessed the utilization and treatment patterns of smok-
ing cessation products in the Mississippi Medicaid Fee-For-Service (FFS) population 
